1. Home
  2. WDC vs ARGX Comparison

WDC vs ARGX Comparison

Compare WDC & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WDC

Western Digital Corporation

N/A

Current Price

$268.32

Market Cap

88.2B

Sector

Technology

ML Signal

N/A

Logo argenx SE

ARGX

argenx SE

N/A

Current Price

$731.49

Market Cap

52.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WDC
ARGX
Founded
1970
2008
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
88.2B
52.0B
IPO Year
1996
2017

Fundamental Metrics

Financial Performance
Metric
WDC
ARGX
Price
$268.32
$731.49
Analyst Decision
Buy
Strong Buy
Analyst Count
23
19
Target Price
$237.26
$991.56
AVG Volume (30 Days)
7.0M
310.4K
Earning Date
04-29-2026
01-01-0001
Dividend Yield
0.19%
N/A
EPS Growth
296.17
N/A
EPS
7.82
N/A
Revenue
$9,520,000,000.00
N/A
Revenue This Year
$31.83
$40.84
Revenue Next Year
$26.32
$22.38
P/E Ratio
$34.06
$33.69
Revenue Growth
N/A
N/A
52 Week Low
$28.83
$510.06
52 Week High
$309.90
$934.62

Technical Indicators

Market Signals
Indicator
WDC
ARGX
Relative Strength Index (RSI) 51.68 32.21
Support Level $168.36 $698.92
Resistance Level $303.20 $856.67
Average True Range (ATR) 15.57 19.24
MACD -3.63 -6.24
Stochastic Oscillator 45.11 17.84

Price Performance

Historical Comparison
WDC
ARGX

About WDC Western Digital Corporation

Western Digital is a leading vertically integrated supplier of hard disk drives. The HDD market is a practical duopoly, with Western Digital and Seagate being the two largest players. Western Digital designs and manufactures its HDDs, with much of the manufacturing and workforce located in Asia. The primary consumers of HDDs are data centers.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: